Recombinant Human F8 therapeutic protein

• Cat.No.: F8-P037H
• Product Overview: This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder. The expression product is the active ingredient of Advate, Alphanate, Bioclate, Helixate, Helixate FS, Hemofil M, Humate-P, Hyate:C, Koate-HP, Kogenate, Kogenate FS, Monarc-M, Monoclate-P, ReFacto, Xyntha and Recombinate.

Specification

• Description: This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
• Source: CHO
• Species: Human
• Molecular Mass: 264.7 kDa
• Protein length: 2332 aa
• AA Sequence: ATRRYYLGAVELSWDYMQSDLGELP VDARFPPRVPKSFPFNTSVVYKKTL FVEFTDHLFNIAKPRPPWMGLLGPT IQAEVYDTVVITLKNMASHPVSLHA VGVSYWKASEGAEYDDQTSQREKED DKVFPGGSHTYVWQVLKENGPMASD PLCLTYSYLSHVDLVKDLNSGLIGA LLVCREGSLAKEKTQTLHKFILLFA VFDEGKSWHSETKNSLMQDRDAASA RAWPKMHTVNGYVNRSLPGLIGCHR KSVYWHVIGMGTTPEVHSIFLEGHT FLVRNHRQASLEISPITFLTAQTLL MDLGQFLLFCHISSHQHDGMEAYVK VDSCPEEPQLRMKNNEEAEDYDDDL TDSEMDVVRFDDDNSPSFIQIRSVA KKHPKTWVHYIAAEEEDWDYAPLVL APDDRSYKSQYLNNGPQRIGRKYKK VRFMAYTDETFKTREAIQHESGILG PLLYGEVGDTLLIIFKNQASRPYNI YPHGITDVRPLYSRRLPKGVKHLKD FPILPGEIFKYKWTVTVEDGPTKSD PRCLTRYYSSFVNMERDLASGLIGP LLICYKESVDQRGNQIMSDKRNVIL FSVFDENRSWYLTENIQRFLPNPAG VQLEDPEFQASNIMHSINGYVFDSL QLSVCLHEVAYWYILSIGAQTDFLS VFFSGYTFKHKMVYEDTLTLFPFSG ETVFMSMENPGLWILGCHNSDFRNR GMTALLKVSSCDKNTGDYYEDSYED ISAYLLSKNNAIEPRSFSQNSRHPS TRQKQFNATTIPENDIEKTDPWFAH RTPMPKIQNVSSSDLLMLLRQSPTP HGLSLSDLQEAKYETFSDDPSPGAI DSNNSLSEMTHFRPQLHHSGDMVFT PESGLQLRLNEKLGTTAATELKKLD FKVSSTSNNLISTIPSDNLAAGTDN TSSLGPPSMPVHYDSQLDTTLFGKK SSPLTESGGPLSLSEENNDSKLLES GLMNSQESSWGKNVSSTESGRLFKG KRAHGPALLTKDNALFKVSISLLKT NKTSNNSATNRKTHIDGPSLLIENS PSVWQNILESDTEFKKVTPLIHDRM LMDKNATALRLNHMSNKTTSSKNME MVQQKKEGPIPPDAQNPDMSFFKML FLPESARWIQRTHGKNSLNSGQGPS PKQLVSLGPEKSVEGQNFLSEKNKV VVGKGEFTKDVGLKEMVFPSSRNLF LTNLDNLHENNTHNQEKKIQEEIEK KETLIQENVVLPQIHTVTGTKNFMK NLFLLSTRQNVEGSYDGAYAPVLQD FRSLNDSTNRTKKHTAHFSKKGEEE NLEGLGNQTKQIVEKYACTTRISPN TSQQNFVTQRSKRALKQFRLPLEET ELEKRIIVDDTSTQWSKNMKHLTPS TLTQIDYNEKEKGAITQSPLSDCLT RSHSIPQANRSPLPIAKVSSFPSIR PIYLTRVLFQDNSSHLPAASYRKKD SGVQESSHFLQGAKKNNLSLAILTL EMTGDQREVGSLGTSATNSVTYKKV ENTVLPKPDLPKTSGKVELLPKVHI YQKDLFPTETSNGSPGHLDLVEGSL LQGTEGAIKWNEANRPGKVPFLRVA TESSAKTPSKLLDPLAWDNHYGTQI PKEEWKSQEKSPEKTAFKKKDTILS LNACESNHAIAAINEGQNKPEIEVT WAKQGRTERLCSQNPPVLKRHQREI TRTTLQSDQEEIDYDDTISVEMKKE DFDIYDEDENQSPRSFQKKTRHYFI AAVERLWDYGMSSSPHVLRNRAQSG SVPQFKKVVFQEFTDGSFTQPLYRG ELNEHLGLLGPYIRAEVEDNIMVTF RNQASRPYSFYSSLISYEEDQRQGA EPRKNFVKPNETKTYFWKVQHHMAP TKDEFDCKAWAYFSDVDLEKDVHSG LIGPLLVCHTNTLNPAHGRQVTVQE FALFFTIFDETKSWYFTENMERNCR APCNIQMEDPTFKENYRFHAINGYI MDTLPGLVMAQDQRIRWYLLSMGSN ENIHSIHFSGHVFTVRKKEEYKMAL YNLYPGVFETVEMLPSKAGIWRVEC LIGEHLHAGMSTLFLVYSNKCQTPL GMASGHIRDFQITASGQYGQWAPKL ARLHYSGSINAWSTKEPFSWIKVDL LAPMIIHGIKTQGARQKFSSLYISQ FIIMYSLDGKKWQTYRGNSTGTLMV FFGNVDSSGIKHNIFNPPIIARYIR LHPTHYSIRSTLRMELMGCDLNSCS MPLGMESKAISDAQITASSYFTNMF ATWSPSKARLHLQGRSNAWRPQVNN PKEWLQVDFQKTMKVTGVTTQGVKS LLTSMYVKEFLISSSQDGHQWTLFF QNGKVKVFQGNQDSFTPVVNSLDPP LLTRYLRIHPQSWVHQIALRMEVLG CEAQDLY
• Endotoxin: < 1.0 EU per μg of the protein
• Purity: >95%
• Storage: Can be stored at +4 centigrade short term (1-2weeks). For long term storage, aliquot and store at -20 centigrade or -70 centigrade. Avoidrepeated freezing and thawing cycles.

Gene Information

• Gene Name: F8 coagulation factor VIII, procoagulant component [ Homo sapiens ]
• Official Symbol: F8
• Synonyms: F8; coagulation factor VIII, procoagulant component; F8C; coagulation factor VIII; DXS1253E; Factor VIIIF8B; FVIII; HEMA; hemophilia A; factor VIII F8B; antihemophilic factor; coagulation factor VIIIc; AHF; F8B
• Gene ID: 2157
• mRNA Refseq: NM_000132
• Protein Refseq: NP_000123
• MIM: 300841
• UniProt ID: P00451
• Chromosome Location: Xq28
• Pathway: Blood Clotting Cascade, organism-specific biosystem; Complement and Coagulation Cascades, organism-specific biosystem; Complement and coagulation cascades, organism-specific biosystem; Complement and coagulation cascades, conserved biosystem; Formation of Fibrin Clot (Clotting Cascade), organism-specific biosystem; Hemostasis, organism-specific biosystem; Intrinsic Pathway, organism-specific biosystem
• Function: copper ion binding; metal ion binding; oxidoreductase activity; protein binding